Clinical Effect of Yinhuang Qingfei Capsules in Treatment of Asymptomatic and Mild/Common Severe Acute Respiratory Syndrome Coronavirus 2 Infection:An Analysis of 242 Cases

[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362 patients with SARS-CoV-2 infection were divided into the treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of average length of hospital stay,mean time for nucleic acid clearance,TCM syndrome score,and progression to severe/critical illness,and clinical outcome was compared between the two groups.[Results]There was a significant difference in the overall response rate between the treatment group and the control group[97.52%(236/242)vs 95.00%(114/120),P<0.05].Compared with the control group,the treatment group had significantly shorter length of hospital stay and time for nucleic acid clearance(P<0.05).After 7 days of treatment,both groups had a significant change in TCM syndrome score,and there was a significant difference in TCM syndrome score between the two groups(P<0.05);after 15 days of treatment,both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.[Conclusions]Compared with the standard treatment regimen alone,standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and time for nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection.

Preventive Effects of Qingfei Yihuo Capsules(清肺抑火胶囊)on Air Pollution Associated Exacerbation of Chronic Obstructive Pulmonary Disease:A Single-blind,Randomized,Controlled Trial

Objective To investigate the efficacy of Qingfei Yihuo Capsules(清肺抑火胶囊,QYCs)in preventing the air pollution associated exacerbation of chronic obstructive pulmonary disease(COPD).Methods This was a prospective,parallel,single-blind,randomized,placebo-controlled trial.Sixty patients with stable Group D COPD were randomly allocated to receive either oral QYCs(intervention group)or placebos(control group,30 cases per group)for 15 days in the presumed high-incidence air pollution season and followed-up for 1 year.Both groups were given individualized Western medicine therapy according to the Global Initiative for Chronic Obstructive Lung Disease criteria as usual.Total and separate numbers of acute exacerbation(AE)associated with striking air pollution was the primary outcomes.Secondary outcomes included total numbers of deteriorating respiratory symptoms and separate numbers associated with striking air pollution,as well as scores of COPD Assessment Test(CAT)and modified Medical Research Council Scale(mMRC).Results All the 60 patients completed the study.There was no statistical significance in total numbers of AE between the two groups(P>0.05).Compared with the control group,a significant reduction in air-pollution associated numbers of deteriorated respiratory symptoms was observed in the intervention group(1.9–1.2 vs.3.6–2.4,P<0.01).At the end of follow-up,there was no significant difference in CAT and mMRC scores between the two groups(P>0.05).Only 2 patients in the intervention group reported diarrhea and recovered after drug discontinuance.Conclusion For patients with Group D COPD,oral QYCs in high-incidence season of air pollution can effectively mitigate respiratory symptoms associated with air pollution,although there was no evidence that it had a significant reductive effect on AEs.(Registered at Chinese Clinical Trial Registry,registration No.ChiCTR-IOR-17013827).